Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

ALPHAEON signs agreement with PhysIOL to develop and commercialize Trifocal lens technology

ALPHAEON Corporation today announced it has entered into a definitive agreement with PhysIOL SA of Belgium, to jointly develop and commercialize an exclusive ALPHAEON-branded Trifocal lens technology. Specific terms of the agreement were not disclosed.

15 Nov 2015

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Among patients with proliferative diabetic retinopathy, treatment with an injection in the eye of the drug ranibizumab resulted in visual acuity that was not worse than panretinal photocoagulation at 2 years, according to a study appearing in JAMA.

15 Nov 2015

Study: Programmable electronic glasses help improve vision in children diagnosed with lazy eye

A new study on lazy eye found that programmable electronic glasses help improve vision in children just as well as the more traditional treatment using eye patches. This "digital patch" is the first new effective treatment for lazy eye in half a century. Results from the first U.S. trial of this device will be presented at AAO 2015, the 119th Annual Meeting of the American Academy of Ophthalmology.

15 Nov 2015

Medflow announces availability of advanced cloud-based EHR system

Medflow, Inc., the leading electronic health record (EHR) and practice management solutions provider for ophthalmologists, announced today the availability of Medflow 2.0 EHR, its most advanced cloud-based EHR system. Medflow 2.0 EHR streamlines the entire workflow, providing logic and guidelines to increase speed of data entry, while also satisfying regulatory requirements.

15 Nov 2015

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

The American Academy of Ophthalmology will pay tribute to outstanding eye physicians and surgeons who have made significant achievements in various areas of the profession. These range from scientific innovation and humanitarian service to education and advocacy. The honorees will be recognized AAO 2015, the Academy's 119th annual meeting in Las Vegas.

13 Nov 2015

AAO announces launch of new online resource to improve eye care for children

The American Academy of Ophthalmology today announced the launch of a new online resource for eye physicians and surgeons dedicated solely to children's ocular diseases and disorders. The Knights Templar Eye Foundation Pediatric Ophthalmology Education Center is an important tool that enables ophthalmologists to better serve the 19 million children worldwide who suffer visual impairment. The new resource will be unveiled this week at AAO 2015, the 119th annual meeting of the American Academy of Ophthalmology.

12 Nov 2015

Purple Button mobile app helps HMC achieve overall goal of improving patient safety, quality

CRG Medical officially announced today the implementation of the ONC for IT award winning Purple Button mobile patient safety application at HMC. The Purple Button, powered by CRG Medical, supports the KB Core High Reliability Patient Safety Evaluation System and has been instrumental in assisting HMC toward their overall goal of improving patient safety, quality and satisfaction.

10 Nov 2015

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

Researchers at the University of California, San Diego School of Medicine developed a method to expand the types of chromosomal abnormalities that noninvasive prenatal testing (NIPT) can detect. The study, published November 9 by Proceedings of the National Academy of Sciences, uses a semiconductor sequencing platform to identify small chromosomal deletions or duplications, such as occur in Cri du Chat Syndrome and DiGeorge Syndrome, with a simple blood test from the expectant mother.

10 Nov 2015

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).

10 Nov 2015

Astellas enters into definitive agreement to acquire Ocata

Astellas Pharma Inc. and Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement.

10 Nov 2015

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.

9 Nov 2015

UCSF scientists identify eye drop chemical that may reverse cataracts

A chemical that could potentially be used in eye drops to reverse cataracts, the leading cause of blindness, has been identified by a team of scientists from UC San Francisco (UCSF), the University of Michigan (U-M), and Washington University in St. Louis (WUSTL).

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

When it comes to fending off disease and helping prevent people from falling ill, the body's immune system -- armed with T-cells that help eliminate cancer cells, virus-infected cells and more -- is second to none. But exactly how the immune system works remains, in many ways, a mystery, as there are numerous cell types whose functions and interactions with our immune systems have not been well understood.

5 Nov 2015

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Allergan plc, a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.

4 Nov 2015

Good news for patients suffering from dry age-related macular degeneration

Scientists have good news for patients who suffer from currently untreatable dry age-related macular degeneration (dry AMD). In a new study, researchers identified a potential target for future therapies to slow the progression of the blinding condition. Published in Investigative Ophthalmology & Visual Science, the findings indicate that treatments currently used for other conditions could also work for dry AMD.

3 Nov 2015

Researchers discover two new structures in cornea of human eye

"It's not everyday that one newly discovers parts of the human body," says Roy S. Chuck, MD, PhD, Chairman Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine.

31 Oct 2015

Saint Louis University ophthalmologist offers tips to manage night vision issues

Owls and cats are at an advantage as the days get darker, but humans may notice their vision takes a hit during their evening commute home as daylight hours shrink.

31 Oct 2015

Ophthalmology News and Research

Further Reading

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

ALPHAEON signs agreement with PhysIOL to develop and commercialize Trifocal lens technology

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Study: Programmable electronic glasses help improve vision in children diagnosed with lazy eye

Medflow announces availability of advanced cloud-based EHR system

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

AAO announces launch of new online resource to improve eye care for children

Purple Button mobile app helps HMC achieve overall goal of improving patient safety, quality

New method may extend use of noninvasive prenatal testing to detect chromosomal abnormalities

L-DOPA drug may delay or prevent age-related macular degeneration

Astellas enters into definitive agreement to acquire Ocata

Nightstar announces $35 million Series B financing round

UCSF scientists identify eye drop chemical that may reverse cataracts

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

Allergan signs licensing agreement with Mimetogen to develop, commercialize tavilermide for treatment of dry eye disease

Good news for patients suffering from dry age-related macular degeneration

Researchers discover two new structures in cornea of human eye

Saint Louis University ophthalmologist offers tips to manage night vision issues

Event guide: The 4th Ophthalmic Drug Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News